Design Therapeutics, Inc. (DSGN) Tops Q2 EPS by 2c

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q2 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

You May Also Be Interested In

• Lutnick Says 'we Trust Anthropic' - Axios
• Active options: NVDA TSLA META AAPL MU DELL AMZN SPCX INTC
• C3 AI (AI) call put ratio 4 calls to 1 put with a focus on September 4 weekly 11 calls into quarter results